Advertisement
Canada markets close in 2 hours 31 minutes
  • S&P/TSX

    21,907.53
    +84.31 (+0.39%)
     
  • S&P 500

    5,127.13
    +62.93 (+1.24%)
     
  • DOW

    38,679.42
    +453.76 (+1.19%)
     
  • CAD/USD

    0.7309
    -0.0005 (-0.07%)
     
  • CRUDE OIL

    78.34
    -0.61 (-0.77%)
     
  • Bitcoin CAD

    84,681.32
    +3,745.19 (+4.63%)
     
  • CMC Crypto 200

    1,337.86
    +60.88 (+4.77%)
     
  • GOLD FUTURES

    2,305.80
    -3.80 (-0.16%)
     
  • RUSSELL 2000

    2,035.98
    +19.87 (+0.99%)
     
  • 10-Yr Bond

    4.5180
    -0.0530 (-1.16%)
     
  • NASDAQ

    16,157.57
    +316.62 (+2.00%)
     
  • VOLATILITY

    13.72
    -0.96 (-6.53%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6788
    -0.0029 (-0.43%)
     

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Zealand Pharma

Company announcement – No. 23 / 2024

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, Denmark, April 19, 2024 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

ADVERTISEMENT

Please see the attached file(s).

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contact:

Adam Lange
Investor Relations Officer
Zealand Pharma
Email: alange@zealandpharma.com

 

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: akrassowska@zealandpharma.com

Attachment